|
Clinical benefit among lenalidomide (LEN)-treated patients (pts) with RBC transfusion-dependent (RBC-TD) low-/int-1-risk myelodysplastic syndromes (MDS) without del(5q). |
|
|
No Relationships to Disclose |
|
|
Honoraria - Celgene; Novartis |
Consulting or Advisory Role - Celgene; Novartis |
Speakers' Bureau - Bristol-Myers Squibb; Celgene; Novartis; Shire |
Research Funding - Celgene |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - Celgene; Novartis |
Research Funding - Celgene; Novartis |
Travel, Accommodations, Expenses - Novartis |
|
|
No Relationships to Disclose |
|
|
|
|
Stock and Other Ownership Interests - COTA |
|
Consulting or Advisory Role - Bristol-Myers Squibb; Novartis |
Speakers' Bureau - Bristol-Myers Squibb; Novartis |
Research Funding - ARIAD; Astellas Pharma; Bristol-Myers Squibb; Celator; Celgene; Novartis; Pfizer |
Expert Testimony - Novartis |
Travel, Accommodations, Expenses - Pfizer |
|
|
Honoraria - Alexion Pharmaceuticals; Celgene; Kyowa Hakko Kirin; Sumitomo Group; Takeda |
Consulting or Advisory Role - Celgene; JCR Pharmaceuticals; Sanofi |
Speakers' Bureau - Celgene |
Research Funding - Takara Bio |
|
|
|
Stock and Other Ownership Interests - Celgene; Novartis; Pfizer |
Consulting or Advisory Role - Celgene; Novartis |
Travel, Accommodations, Expenses - Novartis |
|
|
|
Stock and Other Ownership Interests - Celgene |
|
|
Honoraria - Celgene; Janssen; Novartis |
Research Funding - Celgene |